• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Belimumab.

作者信息

Sanz Iñaki, Yasothan Uma, Kirkpatrick Peter

出版信息

Nat Rev Drug Discov. 2011 May;10(5):335-6. doi: 10.1038/nrd3436.

DOI:10.1038/nrd3436
PMID:21532557
Abstract
摘要

相似文献

1
Belimumab.贝利尤单抗
Nat Rev Drug Discov. 2011 May;10(5):335-6. doi: 10.1038/nrd3436.
2
The discovery and development of belimumab: the anti-BLyS-lupus connection.贝利尤单抗的发现和研发：抗 BLyS 与狼疮的关联。
Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi: 10.1038/nbt.2076.
3
Targeting BLyS in systemic lupus erythematosus.系统性红斑狼疮中针对B淋巴细胞刺激因子的研究
Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):91-6. doi: 10.2174/187221312800166831.
4
[Human monoclonal antibody to B-lymphocyte stimulator (belimumab) and humanized anti-LFA-1 monoclonal antibodies (efalizumab)].[抗B淋巴细胞刺激因子人源单克隆抗体（贝利尤单抗）和人源化抗淋巴细胞功能相关抗原-1单克隆抗体（依法利珠单抗）]
Nihon Rinsho. 2007 Jul;65(7):1239-42.
5
Belimumab: a guide to its use in systemic lupus erythematosus.贝利尤单抗：在系统性红斑狼疮中的应用指南。
BioDrugs. 2012 Jun 1;26(3):195-9. doi: 10.2165/11209060-000000000-00000.
6
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.打破系统性红斑狼疮的僵局：贝利尤单抗，一种有前途的新疗法。
Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575.
7
BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.BAFF/BLyS 抑制剂：治疗系统性红斑狼疮的新前景。
IUBMB Life. 2012 Jul;64(7):595-602. doi: 10.1002/iub.1046. Epub 2012 May 29.
8
Belimumab is approved by the FDA: what more do we need to know to optimize decision making?贝鲁单抗获 FDA 批准：为了优化决策，我们还需要了解哪些信息？
Curr Rheumatol Rep. 2012 Aug;14(4):318-23. doi: 10.1007/s11926-012-0256-4.
9
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?不同 BLyS/BAFF 通路抑制剂之间的生物学差异：我们是否应该期待贝利尤单抗和其他在研抑制剂之间存在差异？
Curr Rheumatol Rep. 2012 Aug;14(4):303-9. doi: 10.1007/s11926-012-0254-6.
10
Treatment for lupus, first in 50 years, offers modest benefits, hope to patients.50年来首个狼疮治疗方法带来适度益处，给患者带来希望。
JAMA. 2011 May 4;305(17):1754-5. doi: 10.1001/jama.2011.548.

引用本文的文献

1
Case of class II lupus nephritis with nephrotic features in the context of belimumab: Intersecting clinical challenge with academic initiative to emphasize social barriers in care.贝利尤单抗治疗下具有肾病特征的II类狼疮性肾炎病例：将临床挑战与学术倡议相结合以强调护理中的社会障碍。
SAGE Open Med Case Rep. 2025 May 13;13:2050313X251336061. doi: 10.1177/2050313X251336061. eCollection 2025.
2
Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.疾病相关B细胞和免疫内型塑造了人类系统性红斑狼疮患者对SARS-CoV-2 mRNA疫苗接种的适应性免疫反应。
Nat Immunol. 2025 Jan;26(1):131-145. doi: 10.1038/s41590-024-02010-9. Epub 2024 Nov 12.
3

本文引用的文献

1
Biological therapy for lupus nephritis-tribulations and trials.狼疮肾炎的生物治疗——困境与探索。
Nat Rev Rheumatol. 2010 Sep;6(9):547-52. doi: 10.1038/nrrheum.2010.117. Epub 2010 Jul 20.
2
B cells as therapeutic targets in SLE.B 细胞作为 SLE 的治疗靶点。
Nat Rev Rheumatol. 2010 Jun;6(6):326-37. doi: 10.1038/nrrheum.2010.68.
3
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.贝利尤单抗治疗活动性系统性红斑狼疮患者的II期随机双盲安慰剂对照剂量范围研究。
Clinical translation of immunomodulatory therapeutics.
免疫调节治疗的临床转化。
Adv Drug Deliv Rev. 2021 Sep;176:113896. doi: 10.1016/j.addr.2021.113896. Epub 2021 Jul 27.
4
A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.狼疮生物制剂的全面综述：超越单一靶点。
Front Immunol. 2020 Oct 2;11:539797. doi: 10.3389/fimmu.2020.539797. eCollection 2020.
5
Development of therapeutic antibodies for the treatment of diseases.治疗性抗体的开发用于疾病的治疗。
J Biomed Sci. 2020 Jan 2;27(1):1. doi: 10.1186/s12929-019-0592-z.
6
Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.在系统性红斑狼疮的更广泛背景下，推进对皮肤红斑狼疮的认识、诊断和治疗。
F1000Res. 2019 Mar 25;8. doi: 10.12688/f1000research.17787.1. eCollection 2019.
7
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.一种临床前定量模型预测了抗 BDCA2 单克隆抗体在人体内的药代动力学/药效学。
J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):817-827. doi: 10.1007/s10928-018-9609-6. Epub 2018 Oct 30.
8
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.一种依赖Toll样受体9（TLR9）的检查点调控B细胞对含DNA抗原的反应。
J Clin Invest. 2017 May 1;127(5):1651-1663. doi: 10.1172/JCI89931. Epub 2017 Mar 27.
9
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.超越肿瘤坏死因子：肿瘤坏死因子超家族细胞因子作为治疗风湿性疾病的靶点
Nat Rev Rheumatol. 2017 Apr;13(4):217-233. doi: 10.1038/nrrheum.2017.22. Epub 2017 Mar 9.
10
Idiopathic Inflammatory Myopathies: Clinical Approach and Management.特发性炎性肌病：临床诊治方法
Front Neurol. 2016 May 20;7:64. doi: 10.3389/fneur.2016.00064. eCollection 2016.
Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.
4
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.慢性给予贝利木单抗（一种B淋巴细胞刺激因子拮抗剂）可减少食蟹猴的组织和外周血B淋巴细胞数量：药代动力学、药效学及毒理学效应
Toxicol Sci. 2006 Jun;91(2):586-99. doi: 10.1093/toxsci/kfj148. Epub 2006 Mar 3.
5
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.LymphoStat-B的产生与特性鉴定，LymphoStat-B是一种拮抗B淋巴细胞刺激因子生物活性的人单克隆抗体。
Arthritis Rheum. 2003 Nov;48(11):3253-65. doi: 10.1002/art.11299.
6
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.前沿：B淋巴细胞刺激因子在系统性红斑狼疮中的作用
J Immunol. 2001 Jan 1;166(1):6-10. doi: 10.4049/jimmunol.166.1.6.
7
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.BLyS：肿瘤坏死因子家族成员及B淋巴细胞刺激因子
Science. 1999 Jul 9;285(5425):260-3. doi: 10.1126/science.285.5425.260.